Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2008

01.02.2008 | Hepatic and Pancreatic Tumors

Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study

verfasst von: Jensen C. C. Tan, MD, Natalie G. Coburn, MD, Nancy N. Baxter, MD, Alex Kiss, PhD, Calvin H. L. Law, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Cholangiocarcinoma (CCA) is associated with poor survival and therapeutic nihilism. To date, there has not been an examination of the surgical management of CCA at a population level.

Methods

Using the Surveillance, Epidemiology and End Results (SEER) database, we identified all patients with intrahepatic CCA diagnosed between 1988 and 2003. Tumors categorized as a single, unilobar lesion with no evidence of vascular invasion were defined as localized. It was then determined whether patients received cancer directed surgery (CDS). Multivariable logistic regression was used to evaluate factors associated with CDS in patients with localized disease. The influence of CDS on overall survival (OS) was evaluated using Kaplan–Meier curves and Cox proportional hazards modeling.

Results

Only 446 (12%) of 3,756 patients with intrahepatic CCA underwent CDS. On multivariable analysis, non-Klatskin tumor (p < 0.01) and younger age (p = 0.02) was associated with CDS. Localized disease was strongly associated with CDS (p < 0.01); however, only 91 (37%) of these 248 patients underwent CDS. Of patients with localized disease, those who had CDS had significantly better survival than those who did not (p < 0.01), with median overall survival (OS) of 44 months versus 8 months, and five-year OS of 42% versus 4%, respectively.

Conclusions

Patients with localized CCA who are selected for CDS are strongly associated with improved survival, with rates approaching that found in single institution studies. However, many patients with localized tumors do not receive potentially curative cancer-directed surgery. Further study is warranted to address the barriers to the delivery of appropriate care to these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472–7PubMedCrossRef Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472–7PubMedCrossRef
3.
Zurück zum Zitat Patel T. Rising incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–7PubMedCrossRef Patel T. Rising incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–7PubMedCrossRef
4.
Zurück zum Zitat Nakeeb A, Pitt HA, Taylor AS, Coleman J, Abrams RA, Piantadosi, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–75 Nakeeb A, Pitt HA, Taylor AS, Coleman J, Abrams RA, Piantadosi, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–75
5.
Zurück zum Zitat De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368–78PubMedCrossRef De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368–78PubMedCrossRef
6.
Zurück zum Zitat Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 2006;23:1287–96PubMedCrossRef Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 2006;23:1287–96PubMedCrossRef
7.
Zurück zum Zitat Kelley ST, Bloomston M, Serafini F, Carey LC, Karl RC, Zervos E, et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004;70:743–9PubMed Kelley ST, Bloomston M, Serafini F, Carey LC, Karl RC, Zervos E, et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004;70:743–9PubMed
8.
Zurück zum Zitat Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005;241:693–702PubMedCrossRef Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005;241:693–702PubMedCrossRef
9.
Zurück zum Zitat Heimbach JK, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB, et al. Transplantation for Hilar Cholangiocarcinoma. Liver Transpl 2004;10:S65–S68PubMedCrossRef Heimbach JK, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB, et al. Transplantation for Hilar Cholangiocarcinoma. Liver Transpl 2004;10:S65–S68PubMedCrossRef
10.
Zurück zum Zitat Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary Cancer: a Phase II trial. J Clin Oncol 2005;23:2332–8PubMedCrossRef Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary Cancer: a Phase II trial. J Clin Oncol 2005;23:2332–8PubMedCrossRef
11.
Zurück zum Zitat Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 2005;109:810–5CrossRef Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 2005;109:810–5CrossRef
12.
Zurück zum Zitat Roayaie S, Guarrera JV, Ye MQ, Thung SN, Emre S, Fishbein TM, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 1998;187:365–72PubMedCrossRef Roayaie S, Guarrera JV, Ye MQ, Thung SN, Emre S, Fishbein TM, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 1998;187:365–72PubMedCrossRef
13.
Zurück zum Zitat Chu KM, Lai EC, Al-Hadeedi SA, Lo CE Jr, Liu CM, Fan CL, et al. Intrahepatic cholangiocarcinoma. World J Surg 1997;21:301–5PubMedCrossRef Chu KM, Lai EC, Al-Hadeedi SA, Lo CE Jr, Liu CM, Fan CL, et al. Intrahepatic cholangiocarcinoma. World J Surg 1997;21:301–5PubMedCrossRef
14.
Zurück zum Zitat Cherqui D, Tantawi B, Alon R, Piedbois P, Rahmouni A, Dhumeaux D, et al. Intrahepatic cholangiocarcioma. Results of aggressive surgical management. Arch Surg 1995;130:1073–8PubMed Cherqui D, Tantawi B, Alon R, Piedbois P, Rahmouni A, Dhumeaux D, et al. Intrahepatic cholangiocarcioma. Results of aggressive surgical management. Arch Surg 1995;130:1073–8PubMed
15.
Zurück zum Zitat Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270–6PubMed Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270–6PubMed
16.
Zurück zum Zitat Lang H, Sotiropoulos GC, Fruhauf NR, Domland M, Andreas P, Kind E, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005;241:134–43PubMed Lang H, Sotiropoulos GC, Fruhauf NR, Domland M, Andreas P, Kind E, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005;241:134–43PubMed
17.
Zurück zum Zitat Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, et al. Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003;10:259–64PubMedCrossRef Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, et al. Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003;10:259–64PubMedCrossRef
18.
Zurück zum Zitat Neuhaus P, Jonas S, Settmacher U, Thelen A, Benckert C, Lopez-Hanninen, et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 2003;388:194–200 Neuhaus P, Jonas S, Settmacher U, Thelen A, Benckert C, Lopez-Hanninen, et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 2003;388:194–200
19.
Zurück zum Zitat Jarnigin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz J, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–17CrossRef Jarnigin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz J, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–17CrossRef
20.
Zurück zum Zitat Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451–8PubMed Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451–8PubMed
21.
Zurück zum Zitat Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Surivival after hepatic resection for colorectal metastases: A 10-year experience. Ann Surg Oncol 2006;13:668–76PubMedCrossRef Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Surivival after hepatic resection for colorectal metastases: A 10-year experience. Ann Surg Oncol 2006;13:668–76PubMedCrossRef
22.
Zurück zum Zitat Chen MF, Jan YY, Wang CS, et al. Clinical experience in 20 hepatic resections for peripheral cholangiocarcinoma. Cancer 1989;64:2226–31PubMedCrossRef Chen MF, Jan YY, Wang CS, et al. Clinical experience in 20 hepatic resections for peripheral cholangiocarcinoma. Cancer 1989;64:2226–31PubMedCrossRef
23.
Zurück zum Zitat Schlinkert RT, Nagorney DM, Van Heerden JA, et al. Intrahepatic cholangiocarcinoma: clinical aspects, pathology and treatment. HPB Surg 1992;5:95–101PubMedCrossRef Schlinkert RT, Nagorney DM, Van Heerden JA, et al. Intrahepatic cholangiocarcinoma: clinical aspects, pathology and treatment. HPB Surg 1992;5:95–101PubMedCrossRef
24.
Zurück zum Zitat O’Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 2004;11:962–9PubMedCrossRef O’Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 2004;11:962–9PubMedCrossRef
25.
Zurück zum Zitat Harrell F. Regression Modeling Strategies. Springer-Verlag, New York, 2002 Harrell F. Regression Modeling Strategies. Springer-Verlag, New York, 2002
26.
Zurück zum Zitat Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006;107:2143–51PubMedCrossRef Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006;107:2143–51PubMedCrossRef
27.
Zurück zum Zitat Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurn J, Virnig BA. Lymph node valuation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005;97:219–25PubMedCrossRef Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurn J, Virnig BA. Lymph node valuation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005;97:219–25PubMedCrossRef
28.
Zurück zum Zitat Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CHL. Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst 2006;98:1474–81PubMed Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CHL. Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst 2006;98:1474–81PubMed
29.
Zurück zum Zitat Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006;244:602–10PubMed Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006;244:602–10PubMed
30.
Zurück zum Zitat Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007;297:278–85PubMedCrossRef Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007;297:278–85PubMedCrossRef
31.
Zurück zum Zitat Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55CrossRef Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55CrossRef
Metadaten
Titel
Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study
verfasst von
Jensen C. C. Tan, MD
Natalie G. Coburn, MD
Nancy N. Baxter, MD
Alex Kiss, PhD
Calvin H. L. Law, MD
Publikationsdatum
01.02.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9627-x

Weitere Artikel der Ausgabe 2/2008

Annals of Surgical Oncology 2/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.